Navigation Links
Zansors Secures Issued Patent for Heart Monitoring Device
Date:5/16/2017

Zansors has secured a patent from U.S. Patent and Trademark Office (USPTO) for a wireless electrocardiogram (ECG or EKG) acquisition and monitoring device. This Zansors’ next-generation intellectual property (IP), will allow heart- monitoring devices to be integrated into clothing, or secured directly onto the skin, making them significantly easier to deploy and use.

Currently, ECG sensors use old-standard technology that requires electrodes to be in contact with the wearer’s skin. Zansors’ new patented device uses capacitive sensors, a well-proven technology similar to the sensors found in cell phones and tablets. These sensors can measure electrical potentials without touching the body.

Zansors is opening up a future that allows patients the same accuracy of readings on their mobile device that they currently can only experience in a clinical setting.

“Zansors’ wearable health tech is going to change how you ‘know yourself,’ but we keep a focus on fact that the user has to have a great experience using the technology,” said Nicole Stout, DPT, Vice President of Medical Affairs at Zansors. “Focusing on a patient-friendly experience with wearables has led directly to this patent.”

According to the January 2017 American Heart Association Heart Disease and Stroke Statistics Update, the number of people diagnosed with heart failure is increasing and projected to rise by 46 percent by 2030, resulting in more than 8 million people with heart failure.

ECGs monitor the heart’s electrical activity and can point to the cause of symptoms of heart disease. Zansors’ new patent will lead to monitoring capability in the hands of consumers who are at-risk for a cardiac episode. People will be able to share their ongoing results with their primary care doctor or cardiologist on a continuous basis, instead of at doctor’s visits. New medications or pacemakers that may affect the heart would be closely monitored to ensure they are effective.

“At Zansors, we have assembled a team of medical researchers, biostatisticians and clinicians to develop unique technologies to support accurate and usable health technology,” said Abhijit Dasgupta, Ph.D., Co-Founder and Chief Data Science Officer at Zansors. “This intellectual property granted by USPTO proves that we are doing that effectively.”

Global law firm DLA Piper’s Reston, Virginia location supported patent prosecution. For more information on this patent, view the summary. Learn more about Zansors’ technologies at http://www.zansors.com, where you can sign up for email updates, and follow us on Facebook and Twitter.

About Zansors

Zansors is a Washington, DC metro-based healthcare innovation company delivering Personal Healthcare Analytics into the hands of consumers via wearable bio-sensors and health apps. Driven by our credo of “know yourself,” Zansors combines evidence-based apps, bioengineering and data analytics, allowing consumers to take charge of their health. Our proprietary biotechnology platform includes micro-sensors and micro-fluidics (also known as “lab-on-a-chip”) backed by a strong portfolio of patents filed. Zansors has previously received 6 funding awards by NIH and has formal partnerships with the University of Michigan and George Washington University.

Read the full story at http://www.prweb.com/releases/2017/05/prweb14336164.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Zansors Announces Issued Patent Protecting Adhesive for Wearable Health Sensors
2. Zansors Wins NIH Grant to Advance Wearable At-Home Affordable Sleep Apnea Detection
3. Dermata Therapeutics, LLC Closes a $5 Million Series 1a Financing and Secures a $5 Million Credit Facility with Silicon Valley Bank
4. Biocept Secures In-Network Provider Agreement with Blue Cross Blue Shield of Texas
5. Renova Therapeutics secures novel AAV vector license for use in metabolic and cardiovascular gene therapy development
6. Sorrento Therapeutics, Inc. Secures $75 Million Loan Facility
7. BerGenBio Secures NOK212 Million Capital Raise
8. Global Leader In Pharmaceutical Cannabinoid Production Secures $7 Million With Tuatara Capital Leading The Series A Round
9. Biocept Secures Agreement with Preferred Provider Organization Prime Health Services
10. CytRx Secures $40 Million Long-Term Loan Facility
11. Zai Lab Secures Over $100M Series B Financing from Leading Healthcare Investors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... 2017 , ... Vortex Biosciences , provider of circulating tumor cell (CTC) ... cells using Vortex microfluidic technology ” in Nature Precision Oncology on May 8th. ... Carlo and Dr. Matthew Rettig at the University of California, Los Angeles. The publication ...
(Date:5/23/2017)... Switzerland (PRWEB) , ... May 23, 2017 , ... ... forces machine manufacturers to re-engineer their control technology again and again. METTLER TOLEDO ... problem for machine manufacturers. The videos illustrate how integration of the ACT350 into ...
(Date:5/21/2017)... ... May 20, 2017 , ... ... the lengthy trial and error process by finding the right antidepressant faster. ... strengthen the doctor-patient relationship through a personalized approach to treatment. , ...
(Date:5/18/2017)... ... May 16, 2017 , ... Clinical Supplies Management (“CSM”), a Great Point Partners ... to grow. CSM has doubled in size over the past six months with ... strategy. , Roger Gasper joins CSM as Chief Financial Officer. Roger has over ...
Breaking Biology Technology:
(Date:4/5/2017)... YORK , April 5, 2017 Today ... is announcing that the server component of the HYPR ... known for providing the end-to-end security architecture that empowers ... HYPR has already secured over 15 million ... makers including manufacturers of connected home product suites and ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
Breaking Biology News(10 mins):